A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 1, 2003, Pages 22-29

  Hersh, A L ^a   Tala Heikkila M ^b   Tala, E ^c   Tosteson, A N A ^a   Fordham von Reyn, C ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c Paimio Hospital   (Finland)

Author keywords

BCG; Cost effectiveness; Non tuberculous mycobacteria; Tuberculosis

Indexed keywords

BCG VACCINE;

ARTICLE; BCG VACCINATION; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; DRUG COST; FINLAND; HIGH RISK POPULATION; HUMAN; INFANT; INFANT DISEASE; INTERMETHOD COMPARISON; MYCOBACTERIOSIS; MYCOBACTERIUM BOVIS; NONHUMAN; PATIENT SELECTION; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; RISK ASSESSMENT; SIDE EFFECT; SIMULATION; TUBERCULOSIS;

BCG VACCINE; COHORT STUDIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FINLAND; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT; MARKOV CHAINS; MASS IMMUNIZATION; PATIENT SELECTION; TUBERCULOSIS;

EID: 0344406671     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Tala E, Romanus V, Tala-Heikkilä M. Bacille Calmette-Guérin vaccination in the 21st century. Eur Respir Mon 1997; 4: 327-353.
2. International Union Against Tuberculosis and Lung Disease. Criteria for discontinuation of vaccination programs using bacille Calmette-Guérin (BCG) in countries with low prevalence of tuberculosis. Tubercle Lung Dis 1994; 75: 179-180.
3. Romanus V, Svensson A, Hallander H O. The impact of changing BCG coverage on tuberculosis incidence in Swedish born children between 1969 and 1989. Tubercle 1992; 73: 150-161.
4. Trnka L, Dankova D, Svandova E. Six years' experience with the discontinuation of BCG vaccination. 2. Cost and benefit of mass BCG vaccination. Tubercle Lung Dis 1993; 74: 288-292.
5. Trnka L, Dankova D, Svandova E. Six years' experience with the discontinuation of BCG vaccination. 1. Risk of tuberculosis infection and disease. Tubercle Lung Dis 1993; 74: 167-172.
6. Sutherland I, Springett V H. The effects of the scheme for BCG vaccination in England and Wales and the consequences of discontinuing the scheme at various dates. J Epidemiol Community Health 1989; 43: 15-24.
7. Genz H. Einschränkung immunprophylaktischer Massnahmen gegen die Kindertuberkulose. Ein Zwischenbericht. Sozialpädiatrie 1980; 2: 285-287.
8. Landmann H, Scharkoff H. Zum aktuellen Stellenwert der Tuberkuloseschutzimpfung. Z Arzl Fortbild (Jena) 1986; 80: 673-676.
9. Wasz-Höckert O, Genz H, Landmann H, Ocklitz H W. The effects of systematic BCG vaccination of newborn on the incidence of postprimary tuberculosis meningitis in childhood. Pädiatr Grenzgeb 1989; 28: 365-370.
10. Deutsches Zentralkommittee zur Bekämpfung der Tuberkulose. Empfehlungen zur BCG-Impfung in der Bundesrepublik Deutschland. Pneumologie 1993; 47: 563-565.
11. Rouillon A, Waaler H. BCG vaccination and the epidemiological situation. Adv Tuber Res 1976; 19: 64-126.
12. Tala-Heikkilä M, Nurmela T, Tala E, Tuominen J. Evaluation of the BCG revaccination programme of school children in Finland. Bull Int Union Tuberc Lung Dis 1991; 66: 57-59.
13. Tala-Heikkilä M, Tuominen J E, Tala E O. Bacillus Calmette-Guérin revaccination questionable with low tuberculosis incidence. Am J Respir Crit Care Med 1998; 157: 1324-1327.
14. Romanus V, Hallander H H, Wahlen P, Olinder-Nielsen A M, Magnusson P H W, Juhlin I. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tubercle Lung Dis 1995; 76: 300-310.
15. Katila M L, Brander E, Backman A. Neonatal BCG vaccination and mycobacterial cervical adenitis in childhood. Tubercle 1987; 68: 291-296.
16. Sonnenberg F A, Beck R J. Markov models in medical research: a practical guide. Medical Decision Making 1993; 13: 322-338.
17. Hersh A L, Black W C, Tosteson A N A. Estimating the population impact of an intervention. Statistical Methods in Medical Research 1999; 3: 311-330.
18. Colditz G A, Berkey C S, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96: 29-35.
19. Trnka L, Dankova D, Svandova E. Six years experience with the discontinuation of BCG vaccination 4. Protective effect of BCG vaccination against the Mycobacterium avium intracellulare complex. Tubercle Lung Dis 1994; 75: 348-352.
20. Gold M R, Seigel J E, Russell L B, Weinstein M C. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
21. Wallgren A. On the contagiousness of childhood tuberculosis. Acta Paediatr Scand 1937; 22: 229-234.
22. Springett V H, Sutherland I. BCG vaccination of schoolchildren in England and Wales. Thorax 1990; 45: 83-88.
23. Swedish Institute for Infectious Disease Control. The Swedish Tuberculosis Index 1994-1999, 2000.
24. Talbot E A, Moore M, McCray E, Binkin N J. Tuberculosis among foreign-born persons in the United States, 1993-1998. JAMA 2000; 284: 2894-2900.